Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06057402

Acronym

MagnetisMM15

Enrollment

Registered

2023-09-28

Start date

2023-10-03

Completion date

2032-02-22

Last updated

2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Multiple Myeloma, Elranatamab, Post Trial Access, Roll-over Study, Extension Study, MM-15, MagnetisMM15, BCMA, BCMA antibody, Magnetism, Bispecific antibody, Elrexfio

Brief summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Detailed description

This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.

Interventions

DRUGElranatamab

Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants must agree to follow the reproductive criteria as outlined in the protocol * Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion criteria

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Design outcomes

Primary

Measure	Time frame
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation	A minimum of 90 days after the last dose of study drug
Incidence of serious adverse events (SAEs)	A minimum of 90 days after the last dose of study drug

Countries

Australia, Canada, China, Japan, Spain, Taiwan, United States

Contacts

CONTACTPfizer CT.gov Call Center

ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021

STUDY_DIRECTORPfizer CT.gov Call Center

Pfizer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026